Chloroquine

證據等級: L5

預測適應症: 10 個

Chloroquine: From Malaria and Autoimmune Disease to Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis

One-Sentence Summary

Chloroquine is a classic aminoquinoline antimalarial drug with established historical use as a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and systemic lupus erythematosus. The TxGNN model predicts it may be effective for Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis (RF+ pJIA), with 0 clinical trials and 2 publications currently supporting this specific direction. This multi-indication analysis also identifies Osteoarthritis as a notably higher-evidence candidate (L1, completed Phase 4 RCT, NCT00805519), warranting parallel consideration.

Quick Overview

Item	Content
Original Indication	Malaria; rheumatoid arthritis; systemic lupus erythematosus (no Singapore registration available)
Predicted New Indication	Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
TxGNN Prediction Score	99.41%
Evidence Level	L4
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on known pharmacological information, chloroquine is an aminoquinoline compound whose key mechanisms include lysosomal stabilization, inhibition of phospholipase A2, suppression of Toll-like receptor (TLR) 7/9 signaling, and downstream reduction of pro-inflammatory cytokines — including IL-1β and TNF-α. These actions also impair the presentation of autoantigens via endosomal antigen-presenting pathways.

Rheumatoid factor-positive polyarticular JIA (RF+ pJIA) is the juvenile arthritis subtype most closely resembling adult seropositive rheumatoid arthritis. It features circulating immune complexes, persistent synovial inflammation, and progressive joint destruction — pathological mechanisms that overlap substantially with adult RA, for which CQ and its analog hydroxychloroquine (HCQ) are well-established DMARDs. The mechanistic extension to RF+ pJIA is therefore scientifically plausible: CQ's TLR7/9 inhibition and immune complex-disrupting effects could theoretically suppress the core inflammatory cascade in this subtype.

However, no clinical trials have directly tested chloroquine in RF+ pJIA specifically. The two available publications address adjacent conditions rather than providing direct evidence for this indication. The mechanistic connection remains an indirect inference, and the evidence base is insufficient to advance beyond hypothesis generation at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8627446	1996	Case Series	The Journal of Pediatrics	Two RF+ polyarticular-onset JRA patients developed accelerated nodulosis on methotrexate; nodules arrested with addition of hydroxychloroquine in one patient — provides indirect evidence that antimalarial drugs have clinical activity in this disease subtype
24334641	2014	Prospective Cohort	The Journal of Rheumatology	Long-term real-world experience with leflunomide in JIA; contextualises DMARD use in the JIA population but does not directly evaluate chloroquine

Singapore Market Information

Chloroquine is currently not registered in Singapore. No product authorizations are on record.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for chloroquine specifically in RF+ pJIA is limited to two peripherally related publications with no clinical trials; the mechanistic rationale, while plausible, remains unvalidated for this particular subtype.

To proceed, the following is needed:

Obtain and review the full chloroquine prescribing information to assess key warnings, contraindications, and monitoring requirements (particularly retinal toxicity and cardiac conduction effects relevant to pediatric long-term use)
Confirm mechanism of action via DrugBank to strengthen the mechanistic rationale section
Evaluate evidence from the closely related juvenile chronic polyarthritis indication (Rank 3 in this report), where a 1991 controlled clinical trial — PMID 1688268 — directly tested Delagil (chloroquine diphosphate) and provides stronger direct clinical evidence
Assess whether hydroxychloroquine, which has an established pediatric safety profile and documented use in JIA (PMID 3517643, US-USSR RCT), would be the more appropriate clinical candidate for this indication rather than chloroquine itself
Consider the broader multi-indication landscape: Osteoarthritis (Rank 5) has L1 evidence from a completed Phase 4 RCT (NCT00805519) and is the most immediately actionable candidate from this analysis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.